Gilead Gets a Buy, Amgen a Hold and ORIC a Vote of Confidence: Wall Street's Latest Biopharma Calls Explained

Gilead Gets a Buy, Amgen a Hold and ORIC a Vote of Confidence: Wall Street's Latest Biopharma Calls Explained

Quick Read Jefferies initiated on Gilead (GILD) with a $180 target (trades at $146.63, up 19.46% YTD) and Amgen (AMGN) at $350 (trades at $376.97, up 15.96% YTD). JPMorgan maintained Oric (ORIC) at $11.65, down 16.07% past week. Jefferies differentiates between Gilead’s underappreciated patent runway through 2036 and Amgen’s 35% rally that has priced in execution, while JPMorgan defends Oric’s pipeline after a competitor-driven selloff. Are y…

Gilead Sciences (NASDAQ:GILD) Now Covered by Analysts at Jefferies Financial Group

Jefferies Financial Group started coverage on Gilead Sciences in a research note on Tuesday. They issued a "buy" rating and a $180.00 target price for the company.

Amgen (NASDAQ:AMGN) Now Covered by Analysts at Jefferies Financial Group

Stock analysts at Jefferies Financial Group started coverage on shares of Amgen (NASDAQ:AMGN – Get Free Report) in a research note issued on Tuesday. The brokerage set a “hold” rating and a $350.00 price target on the medical research company’s stock. Jefferies Financial Group’s target price would suggest a potential downside of 7.15% from the […]